8-K: CVRx Reports Strong Fourth Quarter and Full Year 2024 Results, Driven by U.S. Heart Failure Revenue Growth

CVRx announces a 36% increase in fourth-quarter revenue and a 31% increase in full-year revenue for 2024, fueled by significant growth in the U.S. heart failure market.

Summary

• CVRx reported its financial and operating results for the fourth quarter and full year of 2024.
• Total revenue for Q4 2024 reached $15.3 million, a 36% increase year-over-year.
• U.S. Heart Failure (HF) revenue for Q4 2024 was $14.3 million, representing a 41% increase year-over-year.
• For the full year 2024, total revenue was $51.3 million, a 31% increase compared to the previous year.
• The number of active implanting centers increased to 223 by the end of 2024, a 25% increase from the end of 2023.
• Gross profit for Q4 2024 was $12.8 million, a 33% increase year-over-year, with a gross margin of 83%.
• Net loss for Q4 2024 was $10.7 million, or $0.43 per share, compared to a net loss of $9.2 million, or $0.44 per share, for Q4 2023.
• For the full year 2024, gross profit was $43.0 million, a 30% increase year-over-year, with a gross margin of 84%.
• Net loss for the full year 2024 was $60.0 million, or $2.65 per share, compared to a net loss of $41.2 million, or $1.99 per share, for 2023.
• The company issued 869,059 shares of common stock for gross proceeds of $12.8 million under its at-the-market offering during Q4 2024.
• For the full year 2024, the company issued 3,251,198 shares of common stock for gross proceeds of $33.8 million under its at-the-market offering.
• As of December 31, 2024, cash and cash equivalents were $105.9 million.
• CVRx expects total revenue between $63.0 million and $65.0 million for the full year 2025.
• The company anticipates a gross margin between 83% and 84% and operating expenses between $100.0 million and $104.0 million for 2025.
• For the first quarter of 2025, CVRx expects total revenue between $14.5 million and $15.0 million.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth and increasing adoption of the Barostim system. However, the increasing net losses and operating expenses temper the overall outlook.

Positives

• Significant revenue growth in both Q4 and full-year 2024, driven by U.S. heart failure revenue.
• Increase in the number of active implanting centers, indicating growing adoption of Barostim therapy.
• Strong gross profit and gross margin performance.
• Successful achievement of multiple critical reimbursement milestones.
• Cash and cash equivalents were $105.9 million as of December 31, 2024.

Negatives

• Net losses increased for both the quarter and the full year.
• Gross margin decreased slightly in Q4 2024 due to an increase in the cost per unit.
• SG&A expenses increased significantly, driven by higher compensation and stock-based compensation expenses.
• Revenue in Europe decreased slightly for the full year 2024.

Risks

• The company has a history of significant losses, which are expected to continue.
• CVRx is dependent on a single product, Barostim.
• The company faces risks related to third-party payor coverage and reimbursement for Barostim.
• Competitors may develop products that are more attractive than Barostim.
• The company depends on third-party manufacturers and suppliers.
• The company may face product liability claims and intellectual property lawsuits.

Future Outlook

CVRx expects total revenue between $63.0 million and $65.0 million for the full year 2025, with a gross margin between 83% and 84% and operating expenses between $100.0 million and $104.0 million. For the first quarter of 2025, the company expects total revenue between $14.5 million and $15.0 million.

Management Comments

• Kevin Hykes, President and CEO of CVRx, stated that the company capped off a very strong 2024 with a solid fourth quarter.
• He highlighted the 41% growth in U.S. heart failure revenue and the successful achievement of multiple critical reimbursement milestones.
• Hykes mentioned that the company is focused on three key strategic priorities for 2025: building a world-class sales organization, supporting the development of sustainable Barostim programs, and addressing barriers to adoption.

Industry Context

CVRx operates in the neuromodulation market, specifically targeting cardiovascular diseases with its Barostim System. The company's focus on heart failure positions it within a growing market driven by an aging population and increasing prevalence of heart failure. The company competes with other medical device companies in the cardiovascular space, including those offering alternative therapies for heart failure.

Comparison to Industry Standards

• Comparing CVRx to companies like Nevro Corp (NVRO) and Inspire Medical Systems (INSP), which also operate in the neuromodulation space, CVRx's revenue growth rate is competitive.
• Nevro, focusing on pain management, has shown similar growth patterns in certain periods, while Inspire, targeting sleep apnea, has demonstrated rapid revenue expansion.
• CVRx's gross margin of 84% is generally in line with industry standards for medical device companies, although some companies with higher-margin products may exceed this level.
• Compared to larger cardiovascular device companies like Medtronic (MDT) and Abbott (ABT), CVRx is a smaller player with a more focused product portfolio.
• However, CVRx's specialization in neuromodulation for heart failure provides a unique value proposition.

Stakeholder Impact

• Shareholders will be impacted by the revenue growth and future prospects, but also by the continued net losses.
• Employees will benefit from the company's growth and expansion.
• Patients will have increased access to Barostim therapy.
• Suppliers will see increased demand for components and materials.
• Creditors will be impacted by the company's financial performance and ability to repay debt.

Next Steps

• The company will focus on building a world-class sales organization.
• CVRx will support the development of sustainable Barostim programs to drive deeper utilization.
• The company will address barriers to adoption of Barostim therapy.

Key Dates